---
title: "On the morning of the second day of the National Conference in 2025: Shenghe Pharmaceutical, HISUN, and other pharmaceutical companies enter the venue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263628932.md"
description: "The negotiations for the national medical insurance catalog in 2025 entered their second day. Reporters observed that around 7:30 AM, companies were already waiting outside the National People's Congress conference center. Information verification for entry began around 8:00 AM. The companies participating in the negotiations this morning included Shenghe Pharmaceutical, HISUN, and Sanofi"
datetime: "2025-10-31T00:35:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263628932.md)
  - [en](https://longbridge.com/en/news/263628932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263628932.md)
---

# On the morning of the second day of the National Conference in 2025: Shenghe Pharmaceutical, HISUN, and other pharmaceutical companies enter the venue

The negotiations for the national medical insurance catalog in 2025 have entered their second day. Reporters observed that around 7:30 AM, companies were already waiting outside the Great Hall of the People. Around 8:00 AM, they began to verify information to enter. The companies participating in the negotiations this morning included Shenghe Pharmaceutical, HISUN, and Sanofi

### Related Stocks

- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [600267.CN](https://longbridge.com/en/quote/600267.CN.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [14:53 ETLegendary Racecar Driver, Kurt Busch to Compete in the HSR 2026 NASCAR Classic presented by Goodyear at Le Mans](https://longbridge.com/en/news/286955280.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)
- [Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?](https://longbridge.com/en/news/286962966.md)
- [BUZZ-Relay Therapeutics drops on $175 mln stock offering](https://longbridge.com/en/news/286962133.md)
- [Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances](https://longbridge.com/en/news/286947828.md)